abstract |
This invention relates to methods of treating KRAS-mutant cancers by administering a composition comprising Midostaurin (PKC-412), and methods for increasing the sensitivity of colorectal cancers to radiation, e.g., using Midostaurin (PKC-412) to radiosensitize colorectal cancers or cancer cells. |